Article
Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid.
Frontiers in immunology - 1 Jan 2021
Mainz Jochen G, Arnold Christin, Wittstock Kara, Hipler Uta-Christina, Lehmann Thomas, Zagoya Carlos, Duckstein Franziska, Ellemunter Helmut, Hentschel Julia
Abstract excerpt
In cystic fibrosis (CF) therapy, the recent approval of CF-transmembrane conductance regulator (CFTR) channel modulators is considered to be the major breakthrough. However, the current first-line approach based mainly on pulmonary function to measure effects of the novel therapy, tested by forced expiratory volumes in one second (FEV1), provides restricted sensitivity to detect early structural damages....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
